Stock That Is Worth Exploring Now: Insmed Inc (NASDAQ: INSM)

Insmed Inc (NASDAQ:INSM) does about 3.45M shares in volume on a normal day but saw 4138302 shares change hands in Friday trading. The company now has a market cap of 11.29B USD. Its current market price is $70.00, marking an increase of 12.90% compared to the previous close of $62.00. The 52 week high reached by this stock is $70.65 whilst the lowest price level in 52 weeks is $19.74.

Insmed Inc (INSM) has a 20-day trading average at $64.49 and the current price is -0.92% off the 52-week high compared with 254.61% distance from its 52-week low. The 50-day simple moving average of the closing price is $45.05 and its 200-day simple moving average is $31.40. If we look at the stock’s price movements over the week, volatility stands at 5.67%, which decreases to 5.06% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 70.96 to suggest the stock is overbought.

The consensus objective for the share price is $76.50, suggesting that the stock has a potential upside of 8.5% over the period.


The company shares received a number of brokerage firm price updates over the past month, with the latest being on April 23, 2024 when Truist initiated the stock to “Buy” and issued a price target of $48. Wells Fargo initiated its price target at $55.

Insmed Inc (INSM) stock is up 4.56% over the week and 22.81% over the past month. Its price is 125.88% year-to-date and 238.98% over the past year.

The stock last released its quarterly earnings report for quarter ended 3/31/2024, with the company’s earnings per share (EPS) of -1.78 below consensus estimates by -0.65. The company’s next earnings report forecasts estimating quarterly EPS at -1.19 and -4.57 for whole year. Expected sales for next quarter are $91.77M, which analysts say will come at $353.37M for the current fiscal year and next year at $522.65M. In addition, estimates put the company’s current quarterly revenue at an average of $87.95M.

To reach the target analysts have set, the stock logically needs to grow 8.5 percent from here.

The company has a return on investment of -111.25%. The beta has a value of 1.16. Price to sales ratio is 35.77.